Latest news

• Novartis agrees to help produce Roche’s repurposed COVID-19 drug

  In March, Novartis signed an initial manufacturing agreement with CureVac to help manufacture the latter’s mRNA-based COVID-19 vaccine candidate CVnCoV. ... Deliveries of the CVnCoV doses from Novartis’ Kundl, Austria manufacturing site are expected

• CureVac expands COVID-19 vaccine trial protocol to include variant specification

  Initially, the study aimed to evaluate safety, reactogenicity and immunogenicity of CvnCoV in adult participants. ... The EMA’s Committee for Medicinal Products for Human Use (CHMP) started its rolling review of CVnCoV in February.

• CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate

  German biopharma company CureVac has signed an initial manufacturing agreement with Novartis for its COVID-19 vaccine candidate CVnCoV. ... Deliveries of the CVnCoV doses from Novartis’ Kundl, Austria manufacturing site are expected to begin in summer

• EMA begins rolling review of CureVac’s COVID-19 vaccine

  The European Commission (EC) has signed a supply agreement with CureVac for 405 million doses of CVnCoV. ... Bayer and CureVac also have a manufacturing agreement in place to bolster production of CVnCoV.

• UK and CureVac to jointly develop vaccines against COVID-19 variants

  The study participants will receive a two-dose schedule of either CVnCoV or a placebo to assess the efficacy and safety of the vaccine. ... In January, CureVac partnered with Bayer on the development, supply and key territory operations of CVnCoV.